About Cytochrome P450 4F3
Cytochrome P450 4F3 (CYP4F3) is a protein
from Homo sapiens identified by UniProt accession
Q08477, 520 residues long.
MolForge cross-references it against 0 known binders and
279 disease associations.
Target properties
| Protein name | Cytochrome P450 4F3 |
| UniProt accession | Q08477 |
| Gene | CYP4F3 |
| Organism | Homo sapiens |
| Length | 520 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (279)
Diseases linked to this target (Open Targets).
- cutaneous melanoma · score 0.26
- glioblastoma multiforme · score 0.23
- lung adenocarcinoma · score 0.18
- endometrial cancer · score 0.18
- head and neck squamous cell carcinoma · score 0.13
- urinary bladder cancer · score 0.11
- low grade glioma · score 0.10
- clear cell renal carcinoma · score 0.06
- Acute hepatic failure · score 0.03
- neoplasm · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q08477-F1 | alphafold | PREDICTED | 91.82 | — |
Amino-acid sequence (520 residues)
MPQLSLSSLG LWPMAASPWL LLLLVGASWL LARILAWTYT FYDNCCRLRC FPQPPKRNWF LGHLGLIHSS EEGLLYTQSL ACTFGDMCCW WVGPWHAIVR IFHPTYIKPV LFAPAAIVPK DKVFYSFLKP WLGDGLLLSA GEKWSRHRRM LTPAFHFNIL KPYMKIFNES VNIMHAKWQL LASEGSARLD MFEHISLMTL DSLQKCVFSF DSHCQEKPSE YIAAILELSA LVTKRHQQIL LYIDFLYYLT PDGQRFRRAC RLVHDFTDAV IQERRRTLPS QGVDDFLQAK AKSKTLDFID VLLLSKDEDG KKLSDEDIRA EADTFMFEGH DTTASGLSWV LYHLAKHPEY QERCRQEVQE LLKDREPKEI EWDDLAQLPF LTMCIKESLR LHPPVPAVSR CCTQDIVLPD GRVIPKGIIC LISVFGTHHN PAVWPDPEVY DPFRFDPKNI KERSPLAFIP FSAGPRNCIG QAFAMAEMKV VLGLTLLRFR VLPDHTEPRR KPELVLRAEG GLWLRVEPLS
Explore Cytochrome P450 4F3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets